Quetmolimab: A Deep Dive into KANAb 001 and E-6011 Quest agent, E-6011, shows a novel immunotherapy focused on the PD-1 receptor. Early medical data from the two initiatives, KANAb 001 and E-6011, reveal encouraging https://www.targetmol.com/compound/quetmolimab